Alison Conlin, MD, MPH, medical oncologist, Providence Cancer Institute, stresses the importance of research in breast cancer care and says the stressors and outcomes of the pandemic share similarity to those of a cancer-related outcomes.

Alison Conlin, MD, MPH, medical oncologist, explains how care for HER2+ breast cancer has changed over the last 2 to 4 years compared with other forms of breast cancer—highlighting the approval of four new drugs and indications—and says COVID-19 has impacted cancer care less than other disease…

Barry Gorlitsky, MD, discusses positive treatment outcomes among patients with gout, how to lower hospital readmissions among patients with diluted blood sodium due to kidney function issues, and introduces for the first time a new lower-cost treatment option that he and his colleagues recently…

William Rayford Gwin III, MD, medical oncologist, Seattle Cancer Care Alliance, breaks down some common challenges in treating breast cancer that make it unique compared to other types of cancer, and provides some risk reducing strategies for breast cancer.

Ed Pezalla, MD, CEO, Enlightenment Bioconsult LLC, speaks about the barriers to preventive HIV care, pinpoints how payers can reach at-risk populations, and reviews the US Preventive Services Task Force’s measures requiring health plans to provide access to PrEP.

Jairam Krishnamurthy, MD, FACP, assistant professor of medicine, University of Nebraska Medical Center, reviews what it is like to navigate through breast cancer care with the whole care team—including the patient, pharmacists, other providers, and payers—and also discusses how the costs of breast…

Victor G Vogel, MD, medical oncologist, Geisinger Health System, discusses a variety of risk reducing strategies for breast cancer, including why some are “overdue,” explains why there is a lack in the uptake of medications among patients despite national and global organization support for these…

Ben Isgur, health research institute leader, PwC, discusses recent news from insurers who announced they are reversing their decisions to waive telehealth copays, and provides a future outlook on how the health care landscape should change in order to support virtual care.

Steven Feldman, MD, PhD, Wake Forest University School of Medicine, discusses the real-world effectiveness of dupilumab for the treatment of atopic dermatitis, how this data is relevant for payers, and stresses the importance of studying patient adherence.

Edmund Pezalla, MD, MPH, CEO, Enlightenment Bioconsult LLC, discusses treatment options for multiple sclerosis, highlights results from the ASCLEPIOS I and II studies, and notes why this data can be useful for payers.